Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:17 PM
Ignite Modification Date:
2025-12-24 @ 11:17 PM
NCT ID:
NCT01408056
Eligibility Criteria:
Inclusion Criteria:
* Infants weighing between 4-12kg
* Infants with corrected gestational age 44 weeks - 8 months of age
* Infant with an ulcerated hemangioma
* Informed consent
Exclusion Criteria:
* Ulceration larger than 16cm2
* Ulcerated hemangioma with active bleeding or infection at time of enrollment
* Disease threatening hemangioma meeting criteria for oral propranolol
* Previous treatment with topical/oral corticosteroid or propranolol
* Medical history of congenital heart disease with decreased cardiac output, stroke/cerebral vasculopathy, active reactive airway disease or metabolic disorder
* History of an allergic reaction to Mupirocin or Timolol
* Currently taking medication that would interact with beta-blockers
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
1 Month
Maximum Age:
8 Months
Study:
NCT01408056
Study Brief:
Protocol Section:
NCT01408056